Amgen's Aranesp neither helps nor hurts heart health
This article was originally published in Scrip
Executive Summary
A Phase III trial of Amgen's Aranesp (darbepoetin alfa) in type 2 diabetes patients with chronic kidney disease and anaemia has shown that it is no different than placebo in terms of overall mortality and cardiovascular morbidity, allaying some fears over side-effects.